Rapid Micro Biosystems' Q3 revenue misses estimates, withdraws FY outlook

By Reuters News


Overview

  • US life sciences automation provider's Q3 revenue grew 22% yr/yr but missed analyst expectations

  • Company reported record Q3 gross margin of 25%, up 16 percentage points yr/yr

  • Company signed definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany


Outlook

  • Company is withdrawing its full-year 2026 guidance due to pending acquisition by Merck KGaA


Result Drivers

  • SYSTEM PLACEMENTS AND VALIDATIONS - Co said Q3 revenue growth was driven by placements of seven Growth Direct systems and completion of 12 customer validations

  • GROSS MARGIN EXPANSION - Co attributed record Q3 gross margin of 25% to continued progress in margin expansion initiatives, including higher product and service gross margins


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$9.50 mln

$10 mln (4 Analysts)

Q3 Loss Per Share

$0.23

Q3 Operating Expenses

$13 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Rapid Micro Biosystems, Inc. is $7.00, about 975.3% above its November 13 closing price of $0.65


Reuters Recommended Reads

  • Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall

  • Nov 16 - ALX Oncology Q3 net loss per share narrows

  • Nov 13 - Indaptus Therapeutics Q3 net loss narrows as R&D costs fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk